BioEmix - Company finances
|
EUR
|
2020
From: 2020-08-19
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | - | 30,755 | 34,772 | 386,879 | 138,864 | 281,870 |
| Profit before tax | - | - | - | - | -21,200 | 2,755 |
| Net profit | -2,728 | 306 | 441 | 49,393 | -21,200 | 2,524 |
| Equity | 272 | 578 | 1,019 | 51,123 | 29,924 | 32,447 |
| Liabilities | 1,300 | 13,681 | 17,229 | 82,839 | 30,448 | 42,946 |
| Non-current assets | 0 | 855 | 2,342 | 3,237 | 33,127 | 29,045 |
| Current assets | 1,572 | 13,404 | 15,906 | 130,725 | 27,131 | 45,797 |
| Total assets | 1,572 | 14,259 | 18,248 | 133,962 | 60,258 | 74,842 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | 14,303 | 29,164 | 19,041 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | - | +13.1% | +1012.6% | -64.1% | +103.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -173.5% | 2.1% | 2.4% | 36.9% | -35.2% | 3.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -1002.9% | 52.9% | 43.3% | 96.6% | -70.8% | 7.8% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 1.0% | 1.3% | 12.8% | -15.3% | 0.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | -15.3% | 1.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 4.8 | 23.7 | 16.9 | 1.6 | 1.0 | 1.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 27,680 | 34,772 | 386,879 | 119,023 | 225,496 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
BioEmix - Social security debts
The company had no debts to Sodra
BioEmix - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-01-01 | 2026-01-05 | 2035.49 |
| 2025-10-30 | 2025-11-15 | 6617.0 |
| 2025-08-03 | 2025-08-04 | 52.75 |
| 2025-07-31 | 2025-07-31 | 62.82 |
| 2025-07-30 | 2025-07-30 | 62.58 |
| 2025-01-27 | 2025-01-27 | 0.5 |
| 2025-01-22 | 2025-01-26 | 0.4 |
| 2025-01-01 | 2025-01-21 | 75.19 |
| 2024-12-30 | 2024-12-31 | 75.11 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
BioEmix, UAB (code 305608493) is a Private Limited Liability Company operating in intermediation service activities for specialised retail sale. In the latest financial year, 2025, the company generated revenue of €281.9K and net profit of €2.5K, resulting in a profit margin of 0.9%. Revenue more than doubled year on year in 2025, after declining from €386.9K in 2023 to €138.9K in 2024. Profitability followed a weaker path: the company earned €49.4K in 2023, posted a loss of €21.2K in 2024, and returned to a small profit in 2025. At the end of 2025, total assets stood at €74.8K, with equity of €32.4K and liabilities of €42.9K. Long-term assets were €29.0K and short-term assets €45.8K. The company’s equity ratio was 43.4%, debt-to-equity 1.32, asset turnover 3.77x, ROE 7.8% and ROA 3.4%. Revenue per employee was €281.9K and profit per employee €2.5K.